This audio podcast reports on some of the most important new MS research presented at the ECTRIMS annual meeting, held October 13-16, 2010, in Gothenburg, Sweden. Listen as James D. Bowen, MD, talks about new findings that enhance understanding of MS pathophysiology, testing, neuroregeneration, and cognition. Fred D. Lublin, MD, reviews presentations on emerging and current MS therapies.
Update on Current MS Therapies - Part 2
Dr. Lublin discusses new data on other existing MS therapies: interferon beta, natalizumab, mitoxantrone, and fampridine.
Update on Current MS Therapies - Part 1
Dr. Lublin discusses new data on existing MS therapies: glatiramer acetate and fingolimod, as well as the addition of statins to interferon beta-1a.
Update on Emerging MS Therapies - Part 2
Dr. Lublin describes the latest data presented at ECTRIMS on additional emerging MS therapies (firategrast, cladribine, alemtuzumab, daclizumab, laquinimod, BG00012).
Update on Emerging MS Therapies - Part 1
Dr. Lublin describes the latest data on some of the emerging MS therapies now in late-stage clinical trials (teriflunomide, ocrelizumab and ofatumumab), presented on ECTRIMS.
Testing, Neuroregeneration, and Cognition
In this next section of the podcast, Dr. Bowen looks at the extent to which new data at ECTRIMS answer some important questions about MS testing, neuroregeneration, and cognitive impairment.
MS Pathophysiology: Immunology and Genetics
Dr. Bowen discusses ECTRIMS presentations on lesser-known components of the immune system that contribute to the disease. He also discusses data on genetic causes of MS.